ArticleCureus2025
The Prevalence of Epilepsy Among Patients With Alzheimer's Disease at the King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Alzheimer's disease (AD) and epilepsy are neurological conditions that can affect elderly individuals. The coexistence of these two conditions may lead to additional health challenges and negatively impact patient outcomes. The study aimed to assess the prevalence of epilepsy among patients with AD in Saudi Arabia and to explore factors associated with its occurrence. Methods A cross-sectional retrospective study was conducted at King Abdulaziz Medical City, Riyadh, reviewing the records of patients with AD from 2016 to 2022. Patients with prior epilepsy or without a brain MRI were excluded. Data on demographics, comorbidities, medications, and imaging were analyzed. Results Among 385 patients (mean age 75.5 years) included in the study, epilepsy prevalence was 6%. Diabetes (82%), hypertension (78%), and hyperlipidemia (63%) were common but showed no significant association with epilepsy. Generalized brain atrophy was the most frequent MRI finding. Levetiracetam was the most prescribed antiepileptic drug (77%). Conclusion Epilepsy is more common among patients with AD than in the general population. Early recognition and management are crucial. Further research is needed to understand the risk factors and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.